DexCom earnings beat by $0.03, revenue topped estimates
On Thursday, Cantor Fitzgerald adjusted its outlook on Texas Instruments stock (NASDAQ:TXN), reducing the price target to $170 from the previous $200 while maintaining a Neutral rating. The firm’s analyst cited the current uncertain climate influenced by cyclical and macroeconomic factors, including tariffs, as the reason for the adjustment. According to InvestingPro data, analyst targets for TXN currently range from $125 to $250, reflecting the market’s mixed sentiment. The stock, currently trading at $160.08, has declined over 18% year-to-date.
Texas Instruments recently reported a robust financial performance, surpassing consensus estimates with revenue and earnings per share (EPS) of $8.4 billion and $2.64 respectively, compared to the expected $8.1 billion and $2.30, and even higher than the buy-side anticipation of $7.9 billion and $2.15. Management at Texas Instruments noted a widening recovery and low inventory levels across various markets, now extending to the Industrial sector, and indicated no immediate effects from tariffs on their operations. InvestingPro analysis shows the company maintains strong fundamentals with a healthy current ratio of 4.12 and an impressive gross profit margin of 58.14%.
Despite the positive results, the management team at Texas Instruments has observed no unusual order trends or signs of anxiety regarding inventory levels among customers so far this quarter. However, they acknowledged that given the current environment, it would be logical for customers to prefer holding more inventory rather than less, hinting at potential inventory build-up.
With limited visibility into the second half of the year, the focus now shifts to whether the current strength in Texas Instruments’ performance is a sign of a sustainable cyclical upturn or merely a temporary surge before a potential downturn later in 2025. Cantor Fitzgerald’s revised price target represents a multiple of 31x/26x on their estimated earnings per share for the calendar years 2025 and 2026. The firm remains neutral on the stock, signaling limited upside to the new price target and expressing caution about the potential for a full recovery in the near term.
In other recent news, Texas Instruments has reported first-quarter 2025 earnings that exceeded expectations, with earnings per share (EPS) reaching $1.28 against a forecast of $1.06, and revenue hitting $4.1 billion, surpassing the anticipated $3.91 billion. The company has also provided positive guidance for the second quarter, projecting revenue between $4.17 billion and $4.53 billion. Following these results, KeyBanc Capital Markets adjusted its price target for Texas Instruments to $215, down from $250, while maintaining an Overweight rating, indicating confidence in the stock’s potential to outperform. Similarly, JPMorgan revised its price target from $230 to $195, keeping an Overweight rating, reflecting optimism despite anticipated tariff challenges. Truist Securities also reduced its price target to $171 from $195 but maintained a Hold rating, acknowledging the company’s resilience amid tariff concerns and a cyclical recovery in the semiconductor industry. Texas Instruments has demonstrated flexibility in managing tariff-related challenges, with the capability to shift production to its fabrication plants outside the United States. These developments illustrate the company’s ability to navigate geopolitical uncertainties while maintaining a strong financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.